AOD9604 10mg

What is AOD9604?

AOD9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone corresponding to amino acids 176-191 of the HGH polypeptide. Originally developed by Metabolic Pharmaceuticals in Australia, AOD9604 was designed to isolate the fat-metabolizing activity of HGH from its growth-promoting effects. This makes it a targeted compound for lipid metabolism research without the broader hormonal implications associated with full-length growth hormone. It received GRAS (Generally Recognized as Safe) status from the FDA for use as a food additive, reflecting its favorable safety profile in research.

Mechanism of Action

AOD9604 mimics the lipolytic action of the C-terminal fragment of growth hormone. It stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the formation of new fatty acids) without affecting blood sugar levels or tissue growth. Unlike full-length HGH, AOD9604 does not compete for the growth hormone receptor and does not stimulate IGF-1 production, which means it avoids the proliferative effects associated with growth hormone therapy. Research suggests it acts through a distinct mechanism involving beta-3 adrenergic receptor pathways in adipose tissue.

Research Applications

AOD9604 has been studied primarily in metabolic and obesity research contexts. Key research areas include fat metabolism and lipolysis in adipose tissue, body composition modification without lean mass changes, cartilage and bone repair (where early research has shown unexpected regenerative properties), metabolic syndrome and insulin sensitivity, and comparative studies against full-length HGH to isolate fat-specific metabolic pathways. Several clinical trials have been conducted examining AOD9604 in the context of obesity management.

Product Details

Storage

Store lyophilised vials in a cool, dry place away from light. Once reconstituted with bacteriostatic water, refrigerate at 2-8°C and use within 3-4 weeks. See our reconstitution guide for detailed instructions.